Sutro biopharma

Skip to main content. Sutro Biopharma, Inc. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered sutro biopharma South San Francisco.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology.

Sutro biopharma

Key events shows relevant news articles on days with large price movements. Gossamer Bio Inc. GOSS 4. Kezar Life Sciences Inc. KZR 0. Ovid Therapeutics Inc. OVID 0. Vaxcyte Inc. PCVX 0. Trevi Therapeutics Inc. TRVI 2. XOMA Corp. XOMA 1.

Ovid Therapeutics Inc. Cash from financing Net cash used or generated in financing activities such as dividend payments and loans, sutro biopharma.

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology.

Sutro biopharma

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in

Türkiye haritası corona

EBITDA Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances. Peninsula Bridge. The amount by which a company's cash balance increases or decreases in an accounting period. Free cash flow Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. Trevi Therapeutics Inc. Cash and short-term investments. Unsourced material may be challenged and removed. This article needs additional citations for verification. Previous close. Sign Up for Email Alerts. Listed exchange for this security. The ratio of annual dividend to current share price that estimates the dividend return of a stock.

.

GOSS 4. Hidden categories: Articles with short description Short description is different from Wikidata Articles needing additional references from April All articles needing additional references Articles containing potentially dated statements from All articles containing potentially dated statements Articles with ISNI identifiers. Our innovative Research and development has resulted in six product candidates Our Pipeline Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. XOMA 1. First 1 2 3 4 5 Next Last. Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. The range between the high and low prices over the past 52 weeks. Shares outstanding Total number of common shares outstanding as of the latest date disclosed in a financial filing. Day range. Total assets The total amount of assets owned by a company. Sutro Biopharma, Inc. Key events shows relevant news articles on days with large price movements.